Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$16.85 USD
+0.69 (4.27%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.84 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RNAC 16.85 +0.69(4.27%)
Will RNAC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RNAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNAC
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
RNAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock
Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
Other News for RNAC
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis